Polycystic ovarian syndrome
Conditions
Interventions
A:Diane-35 (2mg ciproterone acetate + 0.035mg ethinylestradiol) for 6 months
B:Drospirenone and Ethinylestradiol Tablets (II)(3mg spironetone + 0.002mg ethinylestradiol) for 6 months
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. meet the 2003 Rotterdam diagnostic criteria: (1) patients with rare ovulation or even no ovulation; (2) clinical symptoms or biochemical manifestations of patients with hyperandrogenemia; (3) polycystic changes of the ovary can be seen on abdominal color doppler ultrasound (vaginal color doppler ultrasound shows that one or both ovaries contain more than 12 follicles with a diameter of 2-9mm); A diagnosis can be made if two of the above three criteria are met. 2. aged = 18 years; 3. women of childbearing age with no childbearing requirement in the next year.
Exclusion criteria
Exclusion criteria: 1. androgen elevation caused by other reasons; 2. those who are known to be allergic to relevant drugs; 3. renal insufficiency; 4. benign and malignant liver tumors or liver diseases; 5. hypoadrenal function; 6. undiagnosed abnormal uterine bleeding; 7. have or have had breast cancer or other estrogen or progesterone sensitive cancers; 8. increased risk of arterial or venous thromboembolic disease: (1) smoking and age >35; (2) present or past deep venous thrombosis or pulmonary embolism; (3) Cerebrovascular diseases; (4) Coronary heart disease; (5) thrombotic valvular heart disease or heart rhythm disease; (6) genetic or acquired hypercoagulant disease; Uncontrolled hypertension; (7) diabetes with vascular disease; (8) headache with focal neurological symptoms; 9. have used any hypoglycemic, lipid-lowering or blood pressure-lowering drugs in the past 3 months; 10. have used compound oral contraceptives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms of hyperandrogenemia (FG score, acne score);Biochemical indicators of hyperandrogenemia;menstrual cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI;Waist-to-hip ratio;Percentage of body fat;Visceral fat area;Visceral fat area;Blood pressure;lipid metabolism;carbohydrate metabolism;Gynecological B ultrasonic; | — |
Countries
China
Contacts
Public ContactYi Liu
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed